Steris Corp. (NYSE:STE) – Stock analysts at Northcoast Research cut their Q1 2018 earnings per share estimates for shares of Steris Corp. in a research report issued to clients and investors on Wednesday. Northcoast Research analyst D. Keiser now expects that the brokerage will post earnings of $0.94 per share for the quarter, down from their previous estimate of $0.95. Northcoast Research has a “Buy” rating on the stock.
Separately, Zacks Investment Research upgraded shares of Steris Corp. from a “sell” rating to a “hold” rating in a report on Thursday, September 8th.
Shares of Steris Corp. (NYSE:STE) traded up 0.65% during midday trading on Friday, reaching $73.10. 619,101 shares of the company’s stock were exchanged. Steris Corp. has a 12-month low of $61.38 and a 12-month high of $78.77. The stock’s 50 day moving average price is $71.29 and its 200 day moving average price is $70.20. The company has a market cap of $6.30 billion, a price-to-earnings ratio of 41.99 and a beta of 1.16.
Steris Corp. (NYSE:STE) last announced its quarterly earnings data on Tuesday, August 9th. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.02. The business had revenue of $638.40 million for the quarter, compared to analysts’ expectations of $639.04 million. Steris Corp. had a net margin of 5.52% and a return on equity of 10.72%. The business’s revenue was up 45.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 27th. Investors of record on Tuesday, August 30th were issued a dividend of $0.28 per share. This is a positive change from Steris Corp.’s previous quarterly dividend of $0.25. The ex-dividend date of this dividend was Friday, August 26th. This represents a $1.12 dividend on an annualized basis and a yield of 1.53%. Steris Corp.’s dividend payout ratio (DPR) is presently 68.71%.
In other news, insider Daniel A. Carestio sold 2,681 shares of the business’s stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $71.04, for a total value of $190,458.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Sudhir K. Pahwa sold 1,028 shares of the business’s stock in a transaction dated Friday, August 26th. The shares were sold at an average price of $70.13, for a total transaction of $72,093.64. The disclosure for this sale can be found here. Corporate insiders own 2.52% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. Bessemer Group Inc. raised its stake in Steris Corp. by 85.8% in the second quarter. Bessemer Group Inc. now owns 1,942 shares of the company’s stock valued at $134,000 after buying an additional 897 shares in the last quarter. CENTRAL TRUST Co raised its stake in Steris Corp. by 334.9% in the second quarter. CENTRAL TRUST Co now owns 2,857 shares of the company’s stock valued at $196,000 after buying an additional 2,200 shares in the last quarter. BKD Wealth Advisors LLC acquired a new stake in Steris Corp. during the second quarter valued at approximately $208,000. Azimuth Capital Management LLC acquired a new stake in Steris Corp. during the second quarter valued at approximately $234,000. Finally, Massmutual Trust Co. FSB ADV acquired a new stake in Steris Corp. during the first quarter valued at approximately $250,000. Institutional investors and hedge funds own 91.58% of the company’s stock.
Steris Corp. Company Profile
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Receive News & Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related companies with MarketBeat.com's FREE daily email newsletter.